{"id":10787,"date":"2025-11-04T16:53:36","date_gmt":"2025-11-04T15:53:36","guid":{"rendered":"https:\/\/pepticoreaminos.net\/?post_type=product&p=10787"},"modified":"2026-01-01T17:29:56","modified_gmt":"2026-01-01T16:29:56","slug":"selank-n-acetyl-peptide","status":"publish","type":"product","link":"https:\/\/pepticoreaminos.net\/en\/product\/selank-n-acetyl-peptide\/","title":{"rendered":"N-Acetyl Selank Amidate 10mg"},"content":{"rendered":"

N-Acetyl Selank Amidate \u2013 Research peptide and neuroregulation<\/h2>\n

N-Acetyl Selank Amidate<\/strong> (NAS-A) is a modified form of the peptide Selank<\/strong>, belonging to the glyproline<\/em> family. This synthetic analogue was designed to improve key pharmacokinetic properties of the original Selank, including stability<\/strong>, half-life<\/strong>, absorption<\/strong>, and its ability to cross the blood-brain barrier (BBB)<\/strong>. The introduced chemical modifications \u2014 N-acetylation and amidation \u2014 increase its enzymatic resistance and receptor affinity<\/strong>, making it a powerful tool for neurochemical<\/strong> and behavioral research.<\/p>\n

Selank was developed in Russia as a nootropic and anxiolytic peptide<\/strong>, derived from a natural sequence of tuftsin<\/em>, an endogenous immunomodulatory tetrapeptide. Experimental studies have shown that the peptide exerts regulatory effects on the central nervous system<\/strong>, modulating the expression of numerous genes related to the GABAergic system, neuronal metabolism, and oxidative stress response.<\/p>\n

\n

Origin and mechanism of action<\/h3>\n

Selank and its variant N-Acetyl Selank Amidate are distinguished by their ability to influence gene expression<\/strong> in the brain. Research conducted at the Institute of Molecular Genetics<\/em> in Moscow has shown that the peptide can activate or silence dozens of genes, particularly those associated with the inhibitory GABA system and the synthesis of Brain-Derived Neurotrophic Factor (BDNF)<\/strong>, a key protein for neuroplasticity, learning, and memory.<\/p>\n

In animal models, administration of Selank reduces the effects of the main inhibitory neurotransmitter, GABA<\/strong>, through an indirect mechanism that increases the affinity of the GABAA<\/sub> receptor<\/strong> for its natural ligand. This effect results in a decrease in anxiety activity without causing dependence or tolerance, typical features of benzodiazepines. The NAS-A version maintains these effects but with greater potency and duration<\/strong> thanks to its structural modifications.<\/p>\n

\n

Selank and anxiety modulation<\/h3>\n

Among the most extensively studied areas is the regulation of anxiety<\/strong>. Comparative experiments between Selank and traditional anxiolytic drugs have shown a similar effect in reducing stress<\/strong> and improving mood, with the advantage of not inducing dependence or excessive sedation. Some preclinical studies suggest that combining Selank and benzodiazepines may offer a synergistic effect in models of chronic mild stress<\/em>, a condition commonly used to simulate treatment-resistant anxiety disorders.<\/p>\n

Molecular analyses indicate that Selank influences up to 45 GABA-related genes<\/strong> out of a total of 84, showing a complex and refined regulatory action on the brain\u2019s neurochemical balance. This makes it highly relevant for research on the genetic basis of stress resilience and psychiatric conditions.<\/p>\n

\n

Crossing the blood-brain barrier<\/h3>\n

One of the main limitations of therapeutic peptides is the difficulty of crossing the blood-brain barrier<\/strong>. However, the glyproline<\/em> family \u2014 to which Selank belongs \u2014 is known for its natural ability to penetrate<\/strong> the central nervous system. The dual structural modification (N-acetylation and amidation) of NAS-A further enhances this feature, allowing for greater brain bioavailability<\/strong> and a longer duration of action.<\/p>\n

\n

Immunomodulatory and anti-inflammatory effects<\/h3>\n

Research conducted at the Mercer University School of Medicine<\/em> has shown that Selank can modulate the production of the cytokine IL-6<\/strong>, reducing systemic and central inflammation levels. IL-6 is a key marker in acute and chronic inflammatory processes, in the fever response, and in pain perception. NAS-A\u2019s ability to influence its expression opens new perspectives for studying the mechanisms linking inflammation, pain, and neurological disorders<\/strong>.<\/p>\n

These findings suggest a possible role of the peptide in reducing neurogenic pain<\/strong> and improving tolerance to physical and psychological stress, confirming the multidimensional nature of its biological activity.<\/p>\n

\n

Coagulation and cerebral ischemia<\/h3>\n

In vivo studies have shown that Selank and the related peptide Semax can regulate the coagulation process<\/strong>, maintaining balance between hypercoagulability and bleeding risk. This property could make it an interesting research molecule in the context of cerebral ischemia<\/strong> and stroke<\/strong>, where neuronal damage is amplified by microthrombosis and vascular inflammation. In animal models, Selank administration has helped protect neurons<\/strong> and improve post-ischemic microvascular perfusion.<\/p>\n

\n

Cognitive effects and the role of BDNF<\/h3>\n

Beyond anxiety reduction, Selank and NAS-A have shown a significant impact on cognitive processes. In experimental models, intranasal administration of the peptide induces an increase in BDNF levels<\/strong> and changes in the expression of over 30 genes linked to memory and learning. Treated animals show greater memory trace stability<\/strong> and more effective long-term information retention<\/strong>.<\/p>\n

Thanks to its greater brain penetration<\/strong>, NAS-A is considered a particularly interesting candidate for nootropic research<\/strong> and for the study of neuroprotection<\/strong> in models of degenerative diseases such as Alzheimer\u2019s and Parkinson\u2019s.<\/p>\n

\n

Significance of N-acetylation and amidation modifications<\/h3>\n

N-acetylation<\/strong> is a common post-translational modification in natural proteins and peptides. In synthetic contexts, it serves to improve molecular stability<\/strong> and reduce enzymatic degradation. Amidation<\/strong>, on the other hand, occurs at the C-terminal end and increases resistance to proteolysis<\/strong>, lipophilicity<\/strong>, and receptor-binding capacity<\/strong>. Together, these modifications make NAS-A a more durable, potent, and easily absorbable version of the original Selank.<\/p>\n

\n

Conclusion<\/h3>\n

N-Acetyl Selank Amidate<\/strong> represents one of the most advanced evolutions in the glyproline<\/em> neuroactive peptide family. With its profile of stability<\/strong>, potency<\/strong>, and selectivity<\/strong>, it is widely used as a research model to study neuronal gene regulation<\/strong>, stress resilience<\/strong>, neuroprotection mechanisms<\/strong>, and synaptic plasticity<\/strong>. The findings obtained so far confirm its potential as a valuable experimental tool in contemporary biomedical research.<\/p>\n

\n

Sources and references<\/h3>\n